Apoptosis induction in osteoclast

Apoptosis induction in osteoclasts" is not a specific molecule or canonical therapeutic target but rather describes a biological process—programmed cell death—in the specialized multinucleated cells responsible for bone resorption. Osteoclast apoptosis is regulated by both extrinsic pathways (such as the Fas/Fas ligand system) and intrinsic mitochondrial pathways, with caspase activation being central to both routes[3]. Estrogen and selective estrogen receptor modulators promote this process indirectly by upregulating Fas ligand expression on neighboring osteoblasts, which then triggers apoptotic signaling in preosteoclasts through cell-cell interactions mediated by the estrogen receptor alpha pathway[1][4]. Therapeutic agents such as denosumab act upstream by inhibiting RANKL-mediated survival signals, thereby favoring apoptotic loss of mature osteoclasts and reducing pathological bone resorption seen in osteoporosis, metastatic cancer to bone, rheumatoid arthritis, and other disorders characterized by excessive skeletal breakdown[2]. However, "apoptosis induction in osteoclast" should not be considered a canonical molecular target; it refers instead to a cellular outcome that can be modulated therapeutically via upstream targets like RANK/RANKL or ERα/FasL. Therefore, this entry is best classified as incorrect when used as a molecular target name.

Activation of death receptor pathways (e.g., Fas/FasL signaling) leading to caspase activation and programmed cell death in osteoclasts[1][3][5] Inhibition of RANKL-RANK interaction, reducing survival signals for osteoclasts and promoting their apoptosis[2]